标题
Glasdegib in newly diagnosed acute myeloid leukemia
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume -, Issue -, Pages 1-9
出版商
Informa UK Limited
发表日期
2021-02-19
DOI
10.1080/14737140.2021.1891885
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
- (2020) Nicholas J. Short et al. Cancer Discovery
- Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial
- (2020) Andrew Henry Wei et al. BLOOD
- Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.
- (2020) Michael Heuser et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting Challenges
- (2020) Steven D. Green et al. Frontiers in Genetics
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
- (2020) Amer M. Zeidan et al. Blood Advances
- Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse
- (2020) Andrew Kent et al. Blood Advances
- Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
- (2020) Andrew H. Wei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
- (2019) Andrew H. Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- New drugs creating new challenges in acute myeloid leukemia
- (2019) Ing S. Tiong et al. GENES CHROMOSOMES & CANCER
- Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
- (2019) Rory M. Shallis et al. BLOOD REVIEWS
- Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
- (2019) Daniel A. Pollyea et al. LEUKEMIA
- Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials
- (2019) Jorge E Cortes et al. Future Oncology
- Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
- (2019) Gail J. Roboz et al. BLOOD
- Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies
- (2018) Robert L. Bowman et al. Cell Stem Cell
- Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
- (2018) Michael R. Savona et al. CLINICAL CANCER RESEARCH
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
- (2018) Jorge E. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
- (2018) Jorge E. Cortes et al. LEUKEMIA
- Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration
- (2017) Justine L. Lam et al. XENOBIOTICA
- Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells
- (2017) Hui Liang et al. Scientific Reports
- Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells
- (2016) Bing Long et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry
- (2015) Erik Hulegårdh et al. AMERICAN JOURNAL OF HEMATOLOGY
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
- (2015) J. Wellbrock et al. CLINICAL CANCER RESEARCH
- Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study
- (2015) Lene Sofie Granfeldt Østgård et al. JOURNAL OF CLINICAL ONCOLOGY
- The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
- (2015) Raoul Tibes et al. Journal of Hematology & Oncology
- GLI2 inhibition abrogates human leukemia stem cell dormancy
- (2015) Anil Sadarangani et al. Journal of Translational Medicine
- Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
- (2015) Michael R Migden et al. LANCET ONCOLOGY
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
- (2015) Giovanni Martinelli et al. Lancet Haematology
- Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers
- (2014) M. Naveed Shaik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
- (2014) A. J. Wagner et al. CLINICAL CANCER RESEARCH
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Targeting hedgehog in hematologic malignancy
- (2012) D. A. Irvine et al. BLOOD
- The Origin and Evolution of Mutations in Acute Myeloid Leukemia
- (2012) John S. Welch et al. CELL
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
- (2012) Aleksandar Sekulic et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis
- (2011) Vera Paulson et al. GENES CHROMOSOMES & CANCER
- Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome
- (2010) Yoon-Jae Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- Hedgehog signaling maintains chemoresistance in myeloid leukemic cells
- (2010) K C S Queiroz et al. ONCOGENE
- Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells
- (2009) Masayoshi Kobune et al. CANCER SCIENCE
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
- (2009) Chen Zhao et al. NATURE
- Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation
- (2008) Christine Dierks et al. CANCER CELL
- Hedgehog: functions and mechanisms
- (2008) M. Varjosalo et al. GENES & DEVELOPMENT
- A paracrine requirement for hedgehog signalling in cancer
- (2008) Robert L. Yauch et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started